Interestingly, inhibition of ATR destabilizes PD-L1, which could sensitize tumor cells to T cell-mediated killing.172 Therefore, the effect of the combination of ATR inhibition and ICIs in cancer immunotherapy needs further study. The gene discussed is ATR; the disease is neoplasm.